Body mass index and cancer risk in patients with type 2 diabetes: A dose-response meta-analysis of cohort studies
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Although obesity has been associated with an increased cancer risk in the general population, the association in patients with type 2 diabetes (T2D) remains controversial. We conducted a dose–response meta-analysis of cohort studies of body mass index (BMI) and the risk of total and site-specific cancers in patients with T2D. A systematic literature search was conducted in PubMed, Scopus, and Medline until September 2020 for cohort studies on the association between BMI and cancer risk in patients with T2D. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random effects models. Ten prospective and three retrospective cohort studies (3,345,031 participants and 37,412 cases) were included in the meta-analysis. Each 5-unit increase in BMI (kg/m 2) was associated with a 6% higher risk of total cancer (RR: 1.06, 95% CI 1.01, 1.10; I 2 = 55.4%, n = 6), and with a 12% increased risk in the analysis of breast cancer (RR: 1.12, 95% CI 1.05, 1.20; I 2 = 0%, n = 3). The pooled RRs showed no association with prostate cancer (RR: 1.02, 95% CI 0.92, 1.13; I 2 = 64.6%, n = 4), pancreatic cancer (RR: 0.97, 95% CI 0.84, 1.11; I 2 = 71%, n = 3), and colorectal cancer (RR: 1.05, 95% CI 0.98, 1.13; I 2 = 65.9%, n = 2). There was no indication of nonlinearity for total cancer (P non-linearity = 0.99), however, there was evidence of a nonlinear association between BMI and breast cancer (P non-linearity = 0.004) with steeper increases in risk from a BMI around 35 and above respectively. Higher BMI was associated with a higher risk of total, and breast cancer but not with risk of other cancers, in patients with T2D, however, further studies are needed before firm conclusions can be drawn.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Several RCTs and systematic reviews/meta-analyses have noted a positive effect of probiotics on glucose, A1C, lipids, and BP.1705–1714”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1714]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The main limitation of these studies is the wide variation in methodologies including differences in the type, formulation, concentration, and duration of exposure to probiotics.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1714]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30150-5 · Cited by 307
RetractedPearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30366-2 · Cited by 265
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Research works printed but not linked: 1
- Sterne, J.A.C., Moher, D. Chapter 10: addressing reporting biases. Cochrane handbook for systematic reviews of intervention. Version 5.1.0 (Updated march 2011) edition. Edited by: Higgins JPT, Green S. 2011, The Cochrane Collaboration.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Fontvieille, E., Viallon, V., Recalde, M., Córdova, R., Jansana, A., Peruchet‐Noray, L., Lennon, H., Heath, A. K., Aune, D., Christakoudi, S., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03114-z · Cited by 65
Self-citationSkriver, C., Friis, S., Knudsen, L. B., Catarig, A., Clark, A. J., Dehlendorff, C., & Mørch, L. S. (2023) · Diabetologia · doi:10.1007/s00125-023-05972-x · Cited by 38
Zhu, W., Peng, K., Zhao, Y. H., Xu, C., Tao, X., Liu, Y., Huang, Y., & Yang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.938760 · Cited by 21
Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 16
Metadata
- Authors
- Soltani, S., Abdollahi, S., Aune, D., & Jayedi, A.
- Affiliations
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
- North Khorasan University of Medical Sciences (IR)
- Oslo University Hospital (NO)
- Semnan University of Medical Sciences (IR)
- Corresponding author
- Jayedi, Ahmad
- Venue
- Scientific Reports
- Published
- 2021-01-28
- Volume
- 11
- Issue
- 1
- Pages
- 2479-2479
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7844243
- OpenAlex
- W3123839075
- Cited by
- 22
- References
- 59
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 4
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- University of Leeds
- Topics
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- type 2 diabetes, cancer risk, obesity, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, dose-response relationship, nonlinear relationship, site-specific cancer risk
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Male, Neoplasms, Risk Factors, Body Mass Index, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body mass index and cancer risk in patients with type 2 diabetes: A dose-response meta-analysis of cohort studies. https://app.cochat.ai/papers/10.1038/s41598-021-81671-0
- The paper
- Soltani, S., Abdollahi, S., Aune, D., & Jayedi, A. (2021). Body mass index and cancer risk in patients with type 2 diabetes: A dose-response meta-analysis of cohort studies. Scientific Reports. https://doi.org/10.1038/s41598-021-81671-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.